We’re addressing an unmet medical need says founder

Severe impact on global economies

”CHRONIC PAIN has a severe impact not only on individual sufferers’ physical and mental health but also on national economies . In the USA, almost 20% of adults suffer from chronic pain (2016) with an estimated annual cost of $560 billion in direct medical costs, lost productivity, and disability programs.

Existing chronic pain drugs are only partly effective, and only for some patients, and they are associated with significant side effects. PharmNovo’s mission is to develop safe and effective medicines for chronic pain treatment.

Our team has taken our lead candidate PN6047 successfully through preclinical studies and it is now engaged in first in man clinical studies. This is a great achievement for a small Biopharma company. Today, I am totally convinced that we can deliver safe and effective medicine for the treatment of chronic, neuropathic pain”.

‍‍

Bengt von Mentzer, founder and chief scientific advisor

‍

Latest news

View all

October 3, 2023

Phase I study completed for PN6047

In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.

PharmNovo presented at the BioStock Investor Meeting

October 3, 2023

PharmNovo presented at the BioStock Investor Meeting

PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.

No abuse potential shown in preclinical studies

September 28, 2023

No abuse potential shown in preclinical studies

We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.

September 10, 2023

Latest progress from PharmNovo at EFIC

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.